Case Reports in Critical Care

Case Reports in Critical Care / 2016 / Article

Case Report | Open Access

Volume 2016 |Article ID 4275651 | 4 pages | https://doi.org/10.1155/2016/4275651

Euglycemic Diabetic Ketoacidosis in a Patient with Cocaine Intoxication

Academic Editor: Moritoki Egi
Received13 Jun 2016
Revised11 Jul 2016
Accepted12 Jul 2016
Published08 Aug 2016

Abstract

Diabetic ketoacidosis (DKA) is characterized by elevated anion gap metabolic acidosis, hyperglycemia, and elevated ketones in urine and blood. Hyperglycemia is a key component of DKA; however, a subset of DKA patients can present with near-normal blood glucose, an entity described as “euglycemic DKA.” This rare phenomenon is thought to be due to starvation and food restriction in insulin dependent diabetic patients. Cocaine abuse is considered a trigger for development of DKA. Cocaine also has anorexic effects. We describe an interesting case of euglycemic DKA in a middle-aged diabetic female presenting with elevated anion gap metabolic acidosis, with near-normal blood glucose, in the settings of noncompliance to insulin and cocaine abuse. We have postulated that cocaine abuse was implicated in the pathophysiology of euglycemic DKA in this case. This case highlights complex physiological interplay between type-1 diabetes, noncompliance to insulin, and cocaine abuse leading to DKA, with starvation physiology causing development of euglycemic DKA.

1. Introduction

The hallmark of diabetic ketoacidosis (DKA) is hyperglycemia, metabolic acidosis, and increased ketones [1]. The absence of hyperglycemia, defined as serum glucose concentration greater than 250 mg/dL [1], makes the diagnosis of DKA less obvious in a patient with elevated serum anion gap metabolic acidosis and positive serum and urine ketones. However, euglycemic DKA has been well described in the literature mainly in type-1 diabetic patients, starvation, gestational diabetes, and more recently the settings SGLT inhibitor use. We describe a case of middle-aged women, who presented with severe metabolic acidosis, ketonemia, and near-normal blood glucose in the settings of noncompliance to insulin and cocaine use leading to poor oral intake. This case report also reviews possible physiologic interplay between lack of insulin and cocaine use leading to DKA.

2. Case

A fifty-seven-year-old female presented to emergency room with altered mental status, nausea, vomiting, and abdominal pain. The patient was in usual state of health 2 days before presentation, when she developed intermittent dull epigastric pain. The patient was able to tolerate the pain initially, but on day of presentation the pain became severe and persistent and she started having nonbilious vomiting. She also became somnolent and tachypneic and therefore the decision was made to bring her to the emergency room. Her past medical history was significant for diabetes mellitus and she was on insulin monotherapy. The family reported that for the last few weeks the patient was noncompliant with using insulin. On initial evaluation her vital signs were remarkable for temperature of 37 degree Celsius, pulse of 120/minutes, blood pressure (BP) of 134/78 mmHg, respiratory rate of 24 breath/minute, and oxygen saturation of 95% on 2-liter nasal cannula. Pertinent examination findings included obtunded patient who did not wake up to deep sternal rub, dry oral mucosa, and a weak gag reflex. Her pulmonary and cardiovascular examination was unremarkable. Admission labs indicated severe uncompensated metabolic acidosis with arterial blood gas showing pH of 7.02, PaCO2 of 14, PaO2 of 134, calculated bicarbonate of 4, and oxygen saturation of 97%. Serum chemistries indicated sodium 137 mEq/L (136–145 mEq/L), potassium 4.4 mEq/L (3.5–5.1 mEq/L), chloride 82 mEq/L (97–109 mEq/L), bicarbonate < 10 mEq/L (23–32 mEq/L), blood urea nitrogen (BUN) 32 mg/dL (7–17 mg/dL), serum creatinine 2.84 mg/dL (0.7–1.1 mg/dL), serum glucose 172 mg/dL (66–111 mg/dL), measured serum anion gap 46 (4–14), and measured serum osmolality 324 mOsm/kg (280–300 mOsm/kg). Her urine analysis was positive for ketones. Urine and serum drug screen was positive for cocaine. Other labs including complete blood count, lactic acid, serum Tylenol levels, and liver function tests were within normal limits. Admission chest roentgenogram was unremarkable (Figure 1).

Given concern for severe uncompensated metabolic acidosis and decreased sensorium, the patient was intubated for airway protection. Initial differential diagnosis included toxic alcohol ingestion, euglycemic diabetic ketoacidosis, alcoholic ketoacidosis, and starvation ketoacidosis. The serum ethanol, methanol, ethylene glycol, and propylene glycol were undetectable on admission labs and serum beta-hydroxybutyrate (BHB) levels were significantly elevated 15.95 mmol/L (0.02–0.27 mmol/L) confirming the diagnosis of euglycemic diabetic ketoacidosis. As the patient’s blood glucose was 172 mg/dL on admission, we initially administered 1 liter bolus of intravenous (IV) 5% Dextrose and 0.45% normal saline (D5-1/2 NS), followed by a maintenance rate of 250 cc/hour, supplemented with 20 mEq of potassium chloride IV per liter of D5-1/2 NS. Insulin drip was initiated at a rate of 0.1 units/kg/hour. Finger stick blood glucose was checked hourly to maintain blood glucose between 150 and 200 mg/dL. Basic metabolic panel and BHB levels were checked at four-hour interval. After initial 4 liters of volume resuscitation, the patient’s anion gap started to close and in 18 hours period her gap closed completely as shown in Table 1.


AdmissionSix hours apartFour hours apartFour hours apartFour hours apartFour hours apart

Sodium137 mEq/L139 mEq/L139 mEq/L138 mEq/L138 mEq/L137 mEq/L
Potassium4.4 mEq/L4.8 mEq/L4.3 mEq/L4.1 mEq/L3.9 mEq/L4.2 mEq/L
Chloride82 mEq/L102 mEq/L103 mEq/L105 mEq/L107 mEq/L107 mEq/L
Bicarbonate<10 mEq/L<10 mEq/L10 mEq/L15 mEq/L21 mEq/L22 mEq/L
Blood urea nitrogen32 mg/dL25 mg/dL22 mg/dL19 mg/dL15 mg/dL14 mg/dL
Creatinine2.84 mg/dL1.82 mg/dL1.69 mg/dL1.66 mg/dL1.20 mg/dL1.06 mg/dL
Glucose172 mg/dL251 mg/dL180 mg/dL198 mg/dL166 mg/dL95 mg/dL
Anion gap46282618108
B-Hydroxybutyrate15.95 mmol/L4.51 mmol/L0.05 mmol/L
pH7.027.137.267.347.367.38

The patient was subsequently transitioned to subcutaneous insulin. Her mentation improved and she was extubated. After extubation patient confirmed that she was on a cocaine binge for 2 days and missed her insulin doses during that time. The patient was transferred out of medical intensive care unit and was discharged from hospital subsequently.

3. Discussion

Diabetic ketoacidosis (DKA) is defined by the American Diabetes Association as having a combination of hyperglycemia (glucose > 250 mg/dL), acidosis (arterial pH < 7.3 and bicarbonate < 15 mEq/L), and ketosis (moderate ketonuria or ketonemia) [1]. Normally, human bodies have balance between insulin levels and their counter regulatory hormones which include glucagon, epinephrine, cortisol, and growth hormone. Any factor that causes decrease in insulin levels or increase in its counter regulatory hormones or both will lead to development of DKA [1].

Rare cases of DKA have been found to occur in the absence of true hyperglycemia; such cases are called euglycemic DKA. This phenomenon was first reported by Munro et al., when 37 out of 211 studied DKA cases were found to be normoglycemic (defined as a serum glucose level of 300 mg/dL (16.7 mmol/L) or lower and a plasma bicarbonate level of 10 mmol/L or lower at presentation) [2]. Thereafter, these criteria have been adjusted to consider serum glucose level of 200 mg/dL as a threshold for the diagnosis of euglycemic DKA. The underlying mechanism of this rare entity is either decreased hepatic production of glucose during fasting states or enhanced urinary excretion of glucose induced by increase in counter regulatory hormones, with the former being the more important; that is, when a diabetic patient is exposed to any triggering factor for DKA and is fasting for any cause while continuing his insulin treatment regularly, the liver will be in a state of glycogen depletion, which in turn leads to decreased hepatic glucose production and increased lipolysis and fatty acid production, and this finally will lead to decreased glucose production while ketone bodies formation is continuous, ending in a state of euglycemic DKA [3]. Some of the causes that have been reported to induce euglycemic DKA include low caloric intake and starvation or prolonged vomiting, pregnancy, pancreatitis, insulin pump use, and SGLT2 inhibitors [49]. Table 2 gives major differentiating points between hyperglycemia DKA and euglycemic DKA.


Hyperglycemic DKAEuglycemic DKA

Blood glucose > 250 mg/dL, arterial pH < 7.3, and serum bicarbonate < 18 mEq/LBlood glucose < 200 mg/dL, arterial pH < 7.3, and serum bicarbonate < 18 mEq/L
Insulin deficiency and increased counter regulatory hormones causing hyperglycemiaInsulin deficiency and increased counter regulatory hormones causing hyperglycemia and starvation from any cause euglycemia
Triggered by infections, concurrent illnesses, and dehydrationAs a result of decreased circulating glucose in starvation, cirrhosis, exogenous insulin use, SGLT-2 inhibitors, pancreatitis, depression, and so forth

Euglycemic DKA can be distinguished from other forms of ketoacidosis including starvation ketoacidosis, and alcoholic ketoacidosis, by clinical history and serum bicarbonate levels. The serum bicarbonate concentration in starvation ketoacidosis is usually more than 18 mEq/L [10]. The absence of other causes of elevated anion gap metabolic acidosis such as lactic acidosis, elevated toxic serum alcohols (methanol, ethylene glycol, etc.), drug toxicity, paraldehyde ingestion, and renal failure can distinguish DKA.

In the current case, the patient presented with severe uncompensated metabolic acidosis, ketonuria, and ketonemia in the absence of true hyperglycemia. After excluding other possibilities of wide anion gap metabolic acidosis including ethanol, methanol, or ethylene glycol ingestion, the diagnosis of euglycemic DKA was made and it was treated accordingly by IV 5% Dextrose, 0.45% normal saline, and insulin drip. The patient was screened positive for cocaine in serum and urine drug screen, and thereafter she admitted that she had been on binge cocaine intake for two days before presentation. Interestingly, cocaine has been reported to be a trigger for DKA in many diabetic patients. This is attributed to cocaine’s stimulatory effect on cortisol, epinephrine, and norepinephrine release from the adrenal gland [11, 12]. This increase in counter regulatory hormones is the underlying cause for having DKA with hyperglycemia in such patients.

In this patient, two counter regulatory factors played a role culminating in development of euglycemic DKA. We hypothesize that, with history of noncompliance to insulin and while being on cocaine binge, the patient developed hyperglycemic DKA for two reasons: firstly, from lack of exogenous insulin and secondly from hyperglycemic effect of cocaine via adrenocortical hormones as described above. Conversely, as cocaine has been shown to cause anorexic effect via suppression of feeding centers in central nervous system [13, 14] and while being on cocaine binge, the patient developed poor oral intake. This starvation effect led to drop in her blood sugar to normal range. Interestingly, the anorexic, thus, hypoglycemic effects of cocaine were more pronounced in our patient, hence overshadowing the initial hyperglycemia resulting in euglycemic DKA.

In conclusion, euglycemic DKA should be included in differential diagnosis in patients presenting with elevated anion gap metabolic acidosis and near-normal blood glucose, especially in the setting of cocaine abuse. Volume resuscitation and insulin drip initiation remain the cornerstone of treatment and early diagnosis through high index of suspicion is paramount in order to start the right treatment.

Competing Interests

The authors declare that they have no competing interests.

References

  1. E. A. Nyenwe and A. E. Kitabchi, “The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management,” Metabolism, vol. 65, no. 4, pp. 507–521, 2016. View at: Publisher Site | Google Scholar
  2. J. F. Munro, I. W. Campbell, A. C. McCuish, and L. J. Duncan, “Euglycaemic diabetic ketoacidosis,” British Medical Journal, vol. 2, no. 5866, pp. 578–580, 1973. View at: Publisher Site | Google Scholar
  3. M. S. Rauf, “Euglycemic ketoacidosis,” Pakistan Journal of Medical Sciences, vol. 24, no. 1, pp. 161–162, 2008. View at: Google Scholar
  4. F. Joseph, L. Anderson, N. Goenka, and J. Vora, “Starvation-induced true diabetic euglycemic ketoacidosis in severe depression,” Journal of General Internal Medicine, vol. 24, no. 1, pp. 129–131, 2009. View at: Publisher Site | Google Scholar
  5. A. Gelaye, A. Haidar, C. Kassab, S. Kazmi, and P. Sinha, “Severe Ketoacidosis Associated with Canagliflozin (Invokana): a safety concern,” Case Reports in Critical Care, vol. 2016, Article ID 1656182, 3 pages, 2016. View at: Publisher Site | Google Scholar
  6. M. Chico, S. N. Levine, and D. F. Lewis, “Normoglycemic diabetic ketoacidosis in pregnancy,” Journal of Perinatology, vol. 28, no. 4, pp. 310–312, 2008. View at: Publisher Site | Google Scholar
  7. J. Rosenstock and E. Ferrannini, “Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors,” Diabetes Care, vol. 38, no. 9, pp. 1638–1642, 2015. View at: Publisher Site | Google Scholar
  8. J. Prater and J. Chaiban, “Euglycemic diabetic ketoacidosis with acute pancreatitis in a patient not known to have diabetes,” Endocrine Practice, vol. 1, no. 2, pp. e88–e91, 2015. View at: Publisher Site | Google Scholar
  9. E. A. Warner, G. S. Greene, M. S. Buchsbaum, D. S. Cooper, and B. E. Robinson, “Diabetic ketoacidosis associated with cocaine use,” Archives of Internal Medicine, vol. 158, no. 16, pp. 1799–1802, 1998. View at: Publisher Site | Google Scholar
  10. A. E. Kitabchi, G. E. Umpierrez, J. M. Miles, and J. N. Fisher, “Hyperglycemic crises in adult patients with diabetes,” Diabetes Care, vol. 32, no. 7, pp. 1335–1343, 2009. View at: Publisher Site | Google Scholar
  11. E. A. Nyenwe, R. S. Loganathan, S. Blum et al., “Active use of cocaine: an independent risk factor for recurrent diabetic ketoacidosis in a city hospital,” Endocrine Practice, vol. 13, no. 1, pp. 22–29, 2007. View at: Publisher Site | Google Scholar
  12. A. S. Kashyap, K. P. Anand, and S. Kashyap, “Cocaine use a risk factor for DKA,” Endocrine Abstracts, vol. 7, abstract P249, 2004. View at: Google Scholar
  13. D. C. Balopole, C. D. Hansult, and D. Dorph, “Effect of cocaine on food intake in rats,” Psychopharmacology, vol. 64, no. 1, pp. 121–122, 1979. View at: Publisher Site | Google Scholar
  14. S. J. Cooper and G. A. van der Hoek, “Cocaine: a microstructural analysis of its effects on feeding and associated behaviour in the rat,” Brain Research, vol. 608, no. 1, pp. 45–51, 1993. View at: Publisher Site | Google Scholar

Copyright © 2016 Asma Abu-Abed Abdin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1394 Views | 632 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.